<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166474</url>
  </required_header>
  <id_info>
    <org_study_id>UoL001452</org_study_id>
    <nct_id>NCT04166474</nct_id>
  </id_info>
  <brief_title>Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin</brief_title>
  <acronym>DoRIS</acronym>
  <official_title>Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helen Reynolds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Disease Institute, Kampala, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Desmond Tutu HIV Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the
      end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir
      when administered with standard, medium and high dose rifampicin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pharmacokinetic parameter Cmin of dolutegravir</measure>
    <time_frame>Day 14, Day 28, Day 42, 5 weeks post anti-tuberculosis treatment</time_frame>
    <description>Change in dolutegravir Cmin when dosed with standard, medium, high dose rifampicin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacokinetic parameter AUC of dolutegravir</measure>
    <time_frame>Day 14, Day 28, Day 42, 5 weeks post anti-tuberculosis treatment</time_frame>
    <description>Change in dolutegravir AUC when dosed with standard, medium, high dose rifampicin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacokinetic parameter Cmax of dolutegravir</measure>
    <time_frame>Day 14, Day 28, Day 42, 5 weeks post anti-tuberculosis treatment</time_frame>
    <description>Change in dolutegravir Cmax when dosed with standard, medium, high dose rifampicin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Grade 3 and above adverse events as assessed by DAIDS (corrected v2.1 July 2017)</measure>
    <time_frame>From first dose of dolutegravir until study completion approximately 2 years</time_frame>
    <description>Number of participants with Grade 3 and above adverse events as assessed by DAIDS (corrected v2.1 July 2017)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hiv</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.</description>
    <arm_group_label>Dolutegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to give informed consent prior to participation

          -  Willing and able to comply with all study requirements

          -  Receiving standard doses of RIF and INH

          -  HIV antibody negative

          -  Male or non-pregnant, non-breastfeeding female

          -  Study participation will not extend length of ATT by more than 4 weeks

        Exclusion Criteria:

          -  &lt; 18 years

          -  Body weight &lt; 50 kg

          -  eGFR &lt; 60 mL/min

          -  Abnormal LFTs including ALT &gt; 2.5 ULN

          -  HIV antibody positive

          -  Non-standard TB regimen (containing RHZE)

          -  Women of childbearing age unless using effective contraception

          -  Family history of sudden cardiac death

          -  Prior history of cardiac disease that precludes the use of low dose digoxin

          -  Medical or psychiatric condition that might affect participation in the study based on
             investigator judgement

          -  Regular consumption of grapefruit or grapefruit juice

          -  ECG abnormalities that preclude the use of low dose digoxin (intermittent complete
             heart block, second degree AV block, supraventricular arrhythmia associated with
             conducting pathways, ventricular tachycardia or fibrillation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saye Khoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Reynolds</last_name>
    <phone>+44 151 706 4129</phone>
    <email>her@liv.ac.uk</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Helen Reynolds</investigator_full_name>
    <investigator_title>Programme manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

